Mounjaro for PCOS: what changes before and after treatment

PCOS-related insulin resistance may make weight loss harder than the BMI number alone suggests — this is a recognised clinical feature, not a personal failing.
Mounjaro is not licensed specifically for PCOS, but PCOS with a qualifying BMI can be a weight-related condition that makes someone eligible under the licensed criteria, subject to individual assessment.
Tirzepatide acts on two gut-hormone pathways (GIP and GLP-1), which influences appetite, blood-sugar regulation and gastric emptying, mechanisms that are relevant to the hormonal picture in PCOS.
Pregnancy is a contraindication: Mounjaro is not suitable during pregnancy, breastfeeding or when actively trying to conceive, and women of childbearing age should use effective contraception throughout treatment.

For women with polycystic ovary syndrome, weight that won't shift despite real effort is one of the most demoralising parts of the condition. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition — which PCOS can qualify as, subject to clinical assessment. Clinical trials in the SURMOUNT programme showed average body-weight reductions of around 20–21% over 72 weeks at the highest dose, though these trials were not PCOS-specific and individual results vary considerably. These are prescription-only medicines; a prescriber reviews your full medical picture before any treatment starts, and suitability for Mounjaro with PCOS is a clinical decision, not an automatic one.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence shows (and what remains uncertain) for PCOS and Mounjaro

Where most people with PCOS start: a weight that fights back

You've probably been told to lose weight. You may have tried, more than once, with results that didn't reflect the effort you put in. That experience is real and well-documented: insulin resistance, which sits at the centre of PCOS for many women, disrupts how the body processes energy and stores fat. It also makes appetite regulation harder. So the frustration you might be feeling as you search this page makes complete sense.

Mounjaro works at a physiological level that's directly relevant here. By activating both GIP and GLP-1 receptors, it reduces appetite, slows how quickly food leaves the stomach, and improves the way the body handles blood sugar. None of those effects are PCOS-specific, but all of them address mechanisms that PCOS tends to work against. For a full picture of how the medicine functions, our Mounjaro overview covers the mechanism in detail.

What's less certain is how much of the weight-loss effect in clinical trials translates specifically to women with PCOS. The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled adults with obesity but not specifically women with PCOS; participants with type 2 diabetes were excluded. That means the headline figures (around 20–21% average weight loss at the maximum dose over 72 weeks) come from a broad population. Results in PCOS will vary, and a prescriber is the right person to set realistic expectations for your situation.

Before and after Mounjaro with PCOS: what changes, and what might take longer

Some changes reported by women with PCOS on GLP-1 and dual-agonist therapies go beyond the number on the scales. Reductions in fasting insulin and improvements in menstrual regularity have been noted in smaller studies and case series, though these are not consistent findings and the evidence base specific to tirzepatide and PCOS is still developing. The NHS tirzepatide page gives a clear patient-level summary of what the medicine is licensed for and its known effects.

The general before-and-after arc for weight loss on Mounjaro tends to follow a recognisable pattern: a slower first month as the body adjusts to the starting dose, more noticeable changes from around weeks eight to twelve as the dose increases, and a different kind of plateau later as appetite regulation stabilises. If you want to see how those changes look in practice for real people, browsing those accounts alongside the early-weeks detail can help set realistic expectations. For an honest account of what the early weeks look like, results in the first week and what one month typically brings are worth reading before starting.

Contraception deserves a specific mention here. Women taking oral contraceptives should add a non-oral method for the first four weeks of Mounjaro and for four weeks after each dose increase, because absorption of the pill can be reduced. This is not optional advice. The NHS England guidance on weight-management injections sets this out plainly. If you are trying to conceive, Mounjaro is not appropriate; speak to your GP or specialist about timing before making any changes.

Who can get a prescription, and what the clinical review covers

A PCOS diagnosis alone does not guarantee a prescription. The licensed criteria for Mounjaro require a BMI of 30 or above, or 27 or above alongside a weight-related health condition, PCOS can meet that second threshold, but the prescriber must also assess your full health picture: other conditions, current medications, contraindications, and your goals. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The decision is clinical, made by a real person, not a tick-box system.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it's submitted. There's no algorithm making suitability calls. How quickly results emerge and what the dose titration schedule looks like are questions the prescriber covers at review, not something to piece together from forums. If you'd like to understand the team behind those reviews, our clinical team page explains who's involved.

For anyone weighing up the private route, the cost context for Mounjaro in the UK and the broader treatment options available are worth looking at before you decide. When you're ready, checking your eligibility takes a few minutes and costs nothing.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions